Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 166

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 166
---
2022, there was a decrease in the percentage
ownership of a significant shareholder (which we define as a holder of at least 5% of our issued and outstanding share capital), ARK Investment
Management LLC, or ARK, (from 6.01% to 0%), based on Form 13F-HR asfiled by ARK on January
24, 2023.

The information above regarding changes in percentage ownership
by major shareholders during the years ended December 31, 2022 through 2024 is based solely on information contained in Schedule 13Gs
and Form 13F (as may be amended) as filed by such persons with the SEC.

97

Record Holders

As of March 20, 2025, there are three shareholders of record of
our ordinary shares, two of which are located in the United States and one that is located in Israel. The majority of our issued and outstanding
ordinary shares were held of record in the United States, in the name of a single record shareholder - Cede & Co., as nominee
for the Depository Trust Company. The number of record holders is not representative of the number of beneficial holders of our ordinary
shares, nor is it representative of where such beneficial holders reside, since the shares held in the name of Cede & Co. are listed
for trading on Nasdaq and the TASE and are beneficially owned by a wide range of underlying beneficial shareholders who hold their shares
in “street name,” including Israeli and other non-U. S. shareholders.

B. Related
Party Transactions

Except as described below or elsewhere in this Annual Report, since
January 1, 2024, we have had no transaction, nor do we have any presently proposed transaction, and neither we nor our subsidiaries have
had any loan, nor do we or our subsidiaries have any presently proposed loan, involving any related party described in Item 7. B. of this
Annual Report.

Agreements with Directors and Officers

Employment Agreements

We have entered into written employment agreements with all of
our executive officers. Each of these agreements contains provisions regarding non-competition, confidentiality of information and assignment
of inventions. The non-competition provision applies for a period that is generally 12 months following termination of employment. The
enforceability of covenants not to compete in Israel and in the United States is subject to limitations.

Equity Awards

See “ Item 6. Directors, Senior Management and Employee -